Navigation Links
UC Davis bench-to-bedside research: Promising treatment in clinical trials
Date:3/26/2009

safety profile and activity in multiple animal models of type 2 diabetes, and has the advantage of inhibiting a novel drug target that differentiates it from currently marketed diabetes medications," Sabry said. "With this promising drug profile, AR9281 has the potential to provide safe and effective therapy for patients with type 2 diabetes either as monotherapy or in combination with existing treatment regimens."

Said Arte's chief medical officer Randall Whitcomb: "The Phase IIa trial will further validate the role of s-EH in the pathophysiology of disease and lay the groundwork for further exploration of s-EH inhibition in treating a broad range of serious diseases including type 2 diabetes, hypertension and inflammatory disorders."

Hammock agrees. "The compound looks quite promising and it's an example of how basic work in insect biology led to a $50 million company--by far the largest Series A financing of an early stage drug in many years-- and a drug in Phase II human clinical trials. This all shows the value of basic research and what we can do to help humanity."


'/>"/>

Contact: Kathy Keatley Garvey
kegarvey@ucdavis.edu
530-754-6894
University of California - Davis
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. UC Davis research shows that newly discovered drug reduces heart enlargement
2. UC Davis researchers find molecule that targets brain tumors
3. UC Davis discovery offers hope for treating kidney cancer
4. UC Davis team refines cancer treatments to reduce potential nerve damage
5. UC Davis researchers exploring gene therapy to fight AIDS
6. UC Davis researchers discover Achilles heel in pancreatic cancer
7. UC Davis researchers discover a key to aggressive breast cancer
8. UC Davis chemical ecologist wins major award
9. UC Davis researchers discover new drug target for inflammatory disease
10. UC Davis researchers define characteristics, treatment options for XXYY syndrome
11. UC Davis researcher leads climate-change discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Davis bench-to-bedside research: Promising treatment in clinical trials
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
(Date:3/20/2015)... OXFORD, Conn. , March 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... Wocket® smart wallet is one of the products featured ... today, March 20th at 11:00 PM EST on the ... travels to Las Vegas , site ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... EAST LANSING, Mich. Researchers at Michigan State University ... natural killer cells fight bacterial infection and reduce inflammation, ... are fiber supplements that serve as food for the ... taken, they can stimulate the growth of the "good" ...
... PhD, research group leader at the new Max Planck ... The Michael J. Fox Foundation for Parkinson,s Research (MJFF). ... to develop a technology that will help scientists working ... LRRK2, a Parkinson,s-related gene. Globally, five million people have ...
... presented at Europe,s leading breast cancer translational research conference ... differences between individual breast cancers. Focused on ... sensitive to important therapies, the new studies will help ... for millions of patients. "Despite major advances in ...
Cached Biology News:Researchers show prebiotic can reduce severity of colitis 2Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinson's drug development tools 2Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinson's drug development tools 3New data improve understanding of breast cancer's multiple varieties 2New data improve understanding of breast cancer's multiple varieties 3New data improve understanding of breast cancer's multiple varieties 4New data improve understanding of breast cancer's multiple varieties 5New data improve understanding of breast cancer's multiple varieties 6
(Date:4/1/2015)... , April 1, 2015  Organovo Holdings, ... company focused on delivering breakthrough 3D bioprinting technology, ... kidney tissue at the 2015 Experimental Biology conference ... "Kidney represents an ideal extension of ... can be tremendously useful in pharmaceutical research," said ...
(Date:4/1/2015)... ROCKVILLE, Md. , April 1, 2015 /PRNewswire/ ... developer of pathogen-specific therapies for serious infections and ... today announced that clinical data supporting the development ... degrade certain beta-lactam intravenous (IV) antibiotics within the ... of the gut microbiome for the prevention of ...
(Date:4/1/2015)... and NEW YORK CITY and ... a leading provider of market research reports and solutions, MarketResearch.com ... indicating that 2015 will be a year of market growth ... executives operating a stem cell company or cord blood bank, ... You must analyze market conditions, predict industry trends, and act ...
(Date:4/1/2015)... National recruitment firm Slone Partners ... as Head of Sales at Optimal Medicine, an international ... , Allen brings over 20 years experience in healthcare ... of companies including Dell Services Healthcare, Medsphere Systems and ... perfect fit for accomplishing the goals Optimal Medicine had ...
Breaking Biology Technology:Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 2Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 3Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 4Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 3Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 4MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 2MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 4Slone Partners Fills Head of Sales at Optimal Medicine 2
... Masimo Corporation,(Nasdaq: MASI ), the inventor of ... to present at the Deutsche Bank 33rd,Annual Health Care ... May 6, 2008 at 9:30 a.m. ET. Joe E. ... of the presentation will be available on the Masimo ...
... first,paragraph. The timing of the live teleconference should have read: "9:00 am ... copy follows: Resverlogix ... ... is pleased to announce that it will host a live,teleconference on May 8, 2008 ...
... to Provide Unique Insights and ... SOUTH SAN FRANCISCO, May 1 Monogram,Biosciences, Inc. ... HER1,and HER3 Quantitative Protein Assays are now available for ... and,HER3 assays provide unique, quantitative measurements of protein expression,and ...
Cached Biology Technology:Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference 2/C O R R E C T I O N from Source -- Resverlogix Corp./ 2HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 2HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 3HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 4HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 5
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
Mouse monoclonal antibody to PPP2R2C - protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform...
Mouse polyclonal antibody to BTG2 - BTG family, member 2...
...
Biology Products: